Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
GRAL Stock Chart & Stats
$54.04
-$1.19(-6.66%)
At close: 4:00 PM EST
$54.04
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$20.44 - $118.84
Previous CloseN/A
Volume371.20K
Average Volume (3M)1.69M
Market Cap
$2.06B
Enterprise Value$1.87B
Total Cash (Recent Filing)$904.43M
Total Debt (Recent Filing)$98.01M
Price to Earnings (P/E)―
Beta2.65
Next Earnings
May 19, 2026EPS Estimate
-2.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding38,982,224
10 Day Avg. Volume3,538,443
30 Day Avg. Volume1,691,342
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue12.69
Enterprise Value/Gross Profit-29.85
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$93.20Price Target Upside72.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-11
Revenue Forecast (FY)$179.37M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FundingRecent financing and a reduction in cash burn strengthened the balance sheet, providing funding runway to support planned regulatory submissions and commercial rollout.
Clinical EvidenceAdding Galleri to standard screening reduced late-stage diagnoses in a pre-specified group of deadly cancers, supporting the test's clinical value and potential to increase early detection rates.
Commercial TractionStrong growth in Galleri testing volume has driven revenue above expectations and supports continued commercial expansion as the firm scales its U.S. sales force.
Bears Say
Coverage Uncertainty From Trial OutcomeThe NHS-Galleri trial not meeting its primary endpoint creates uncertainty for Medicare and commercial payer coverage decisions, which may delay broader reimbursement.
Regulatory And Execution RiskReliance on a stage-shift surrogate instead of a mortality endpoint, combined with remaining cash-burn considerations, raises execution and regulatory risk that could limit label scope and slow adoption.
Valuation RiskA sharp stock run-up and a premium valuation relative to diagnostic peers reduce near-term upside and increase downside risk if clinical or regulatory updates disappoint.
GRAIL Inc News
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $20.44 and its highest was $118.84 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $2.06B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is May 19, 2026 which is in 74 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Feb 19, 2026. The company reported -$2.44 earnings per share for the quarter, beating the consensus estimate of -$2.7 by $0.26.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Undervalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -2.75.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 38,982,224 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$2.44 in its last earnings report, beating expectations of -$2.7. Following the earnings report the stock price went down -50.547%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.20 (72.46% Upside)
$93.20 (72.46% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.10%
12-Months-Change
Fundamentals
Return on Equity
-16.07%
Trailing 12-Months
Asset Growth
-7.01%
Trailing 12-Months
Company Description
GRAIL Inc
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial momentum (36% volume growth, 26% U.S. revenue growth, expanded prescriber base), supportive safety and performance signals (fourfold detection rate increase, >20% Stage IV reduction in later rounds, no serious safety events), successful regulatory progress (PMA submitted) and a strong cash position. Offsetting these positives, the NHS‑Galleri trial missed its primary combined Stage III+IV endpoint, stage distribution anomalies require extended follow‑up (6–12 months), and the company still reports substantial operating losses and faces future royalty headwinds. On balance, the breadth of positive commercial, regulatory and clinical signals — plus improved profitability trends and a solid cash runway — outweigh the notable challenges and uncertainties.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$93.20
▲(72.46% Upside)
Technical Analysis
Ownership Overview
21.22% Insiders
12.95% Mutual Funds
8.64% Other Institutional Investors
43.85% Public Companies and Individual Investors